Eli Lilly Designs P-Tau Biomarker Assay for Early Alzheimer’s Disease Diagnosis
The Pharma Data
NOVEMBER 10, 2020
Biomarkers will be critical to developing precision medicine for Alzheimer’s disease. Therefore, Eli Lilly is developing an assay that measures P-tau 217 in blood. We wanted a tau antibody that would bind to the expressed forms of tau, so we developed a very specific assay,” Dage said. ADNI trial.
52 
Let's personalize your content